StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.44−1.12 (-3.92%)

Close on Nov 16, 2026Market cap $4.76BP/E –Yield –

Cogent Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Cogent Biosciences's operating margin for the twelve months ending Dec 31, 2020 was -1044.3%. For fiscal 2020 it was -1044.3%, against -143.0% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2020Dec 31, 2020-1044.3%−901.3
FY2019Dec 31, 2019-143.0%+226.9
FY2018Dec 31, 2018-369.9%−57.1
FY2017Dec 31, 2017-312.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2020Sep 30, 2020-18333.0%−17153.0
Q2 FY2020Jun 30, 2020-1402.1%−1066.2
Q1 FY2020Mar 31, 2020-87.3%+300.5
Q4 FY2019Dec 31, 201914.7%+251.3
Q3 FY2019Sep 30, 2019-1180.0%−662.3
Q2 FY2019Jun 30, 2019-335.9%+230.7
Q1 FY2019Mar 31, 2019-387.8%−73.2
Q4 FY2018Dec 31, 2018-236.6%+87.4
Q3 FY2018Sep 30, 2018-517.7%−210.1
Q2 FY2018Jun 30, 2018-566.6%−276.4
Q1 FY2018Mar 31, 2018-314.7%+17.5
Q4 FY2017Dec 31, 2017-324.1%–
Q3 FY2017Sep 30, 2017-307.6%–
Q2 FY2017Jun 30, 2017-290.2%–
Q1 FY2017Mar 31, 2017-332.2%–

More Cogent Biosciences figures

See a number that looks wrong?